Shire PLC (SHP) Given Average Recommendation of “Buy” by Analysts
Shire PLC (LON:SHP) has received a consensus recommendation of “Buy” from the twenty research firms that are covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is GBX 5,246.88 ($69.95).
SHP has been the topic of several research reports. Liberum Capital reissued a “hold” rating and issued a GBX 4,900 ($65.32) target price on shares of Shire in a research report on Thursday, August 3rd. Credit Suisse Group reaffirmed an “outperform” rating and set a GBX 5,350 ($71.32) price target on shares of Shire in a research report on Friday, August 4th. J P Morgan Chase & Co reaffirmed an “overweight” rating on shares of Shire in a research report on Friday, August 4th. Deutsche Bank AG reaffirmed a “buy” rating and set a GBX 6,000 ($79.99) price target on shares of Shire in a research report on Friday, August 4th. Finally, Beaufort Securities reaffirmed a “long term buy” rating and set a GBX 4,900 ($65.32) price target (down from GBX 6,200 ($82.66)) on shares of Shire in a research report on Friday, August 4th.
Shire (LON SHP) traded down GBX 45 ($0.60) during midday trading on Monday, hitting GBX 3,666 ($48.87). The company had a trading volume of 1,281,851 shares, compared to its average volume of 2,950,000. Shire has a 52-week low of GBX 3,435.50 ($45.80) and a 52-week high of GBX 5,067 ($67.55).
In other Shire news, insider Anne Minto bought 190 shares of the company’s stock in a transaction dated Friday, September 29th. The shares were purchased at an average cost of GBX 3,785 ($50.46) per share, for a total transaction of £7,191.50 ($9,587.39).
WARNING: “Shire PLC (SHP) Given Average Recommendation of “Buy” by Analysts” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/shire-plc-shp-given-average-recommendation-of-buy-by-analysts/1729433.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.